Video—As Sanofi plans 70M flu shots in U.S., Ryan Riboldi explains role of new quality facility

Sanofi Pasteur opened a new quality testing facility in Swiftwater, Pennsylvania.

As it ramps up flu vaccine production, Sanofi Pasteur has opened a new quality testing facility at its Swiftwater, Pennsylvania, campus. A $65 million investment, the building will play an important role in testing tens of millions of flu vaccine doses each year, with additional capabilities to test other current and future vaccines. The company plans to ship 70 million flu shot doses to the U.S. market this year.

"It signifies growth," Ryan Riboldi, associate vice president of quality operations at Sanofi Pasteur US, told FiercePharma in an interview at the site. "As a worldwide leader in flu, our flu market is continuing to expand and our ability to test our vaccines as quickly as we can to get them to the people that need them becomes vitally important."

RELATED: The flu vaccines are coming: GSK, Sanofi ship the first of more than 150M doses headed to U.S.

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.

Flu vaccines spend 70% of their life cycle in quality testing, according to Riboldi, undergoing about 240 tests throughout the production process. The facility opened in May 2017 and is one of dozens of buildings at Sanofi's Swiftwater site.